Zafgen Inc. (NASDAQ:ZFGN) was up 3.6% on Monday . The stock traded as high as $3.17 and last traded at $3.15, with a volume of 498,109 shares trading hands. The stock had previously closed at $3.04.

Several equities research analysts have recently weighed in on ZFGN shares. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a research note on Tuesday, July 26th. Canaccord Genuity set a $4.00 target price on shares of Zafgen and gave the company a “hold” rating in a research note on Thursday, July 21st. Royal Bank Of Canada reissued an “outperform” rating and issued a $19.00 target price on shares of Zafgen in a research note on Tuesday, April 5th. Leerink Swann reissued a “hold” rating and issued a $6.00 target price on shares of Zafgen in a research note on Monday, April 11th. Finally, FBR & Co reissued a “buy” rating and issued a $20.00 target price on shares of Zafgen in a research note on Monday, April 4th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $9.22.

The company has a 50-day moving average of $5.44 and a 200-day moving average of $6.38. The company’s market cap is $86.45 million.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.09. During the same quarter in the previous year, the business posted ($0.53) earnings per share. On average, analysts forecast that Zafgen Inc. will post ($2.62) earnings per share for the current fiscal year.

In other Zafgen news, CFO Patricia L. Allen bought 16,000 shares of the stock in a transaction on Tuesday, July 26th. The shares were bought at an average price of $3.12 per share, with a total value of $49,920.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Frances K. Heller bought 10,000 shares of the stock in a transaction on Friday, July 22nd. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $29,900.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $29,900. The disclosure for this purchase can be found here.

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.